Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11442386 | PMC |
| http://dx.doi.org/10.3389/fpsyg.2024.1477863 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Once-Weekly Insulin: A Breakthrough in Diabetes Management or an Unresolved Challenge?
Br J Hosp Med (Lond)
January 2025
Department of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan.
The advent of once-weekly insulin icodec is a promising development in the care of individuals with diabetes. These once-weekly formulations aimed to improve patient adherence and quality of life for patients who find daily injection administration challenging. Insulin icodec has demonstrated comparable glycemic control to conventionally used daily basal insulins, such as insulin glargine and degludec, in the ONWARDS clinical trials.
View Article and Find Full Text PDFFinerenone: Do We Really Need an Additional Therapy in Type 2 Diabetes Mellitus and Kidney Disease?
Br J Hosp Med (Lond)
January 2025
Nephrology Department, Sunderland Royal Hospital, Sunderland, UK.
Patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) face considerable cardiorenal morbidity and mortality despite existing therapies. Recent clinical trials demonstrate the efficacy of finerenone, a novel non-steroidal mineralocorticoid receptor antagonist, in reducing adverse renal and cardiovascular outcomes. This editorial briefly reviews the evidence and its implications for clinical practice, advocating the use of finerenone in these high-risk patients in combination with currently established treatment agents.
View Article and Find Full Text PDFTesting for myelin oligodendrocyte glycoprotein antibodies: Who, what, where, when, why, and how.
Mult Scler
January 2025
Department of Neurology, Mayo Clinic, Rochester, MN, USA.
Testing for myelin oligodendrocyte glycoprotein immunoglobulin G antibodies (MOG-IgG) is essential to the diagnosis of MOG antibody-associated disease (MOGAD). Due to its central role in the evaluation of suspected inflammatory demyelinating disease, the last 5 years has been marked by an abundance of research into MOG-IgG testing ranging from appropriate patient selection, to assay performance, to utility of serum titers as well as cerebrospinal fluid (CSF) testing. In this review, we synthesize current knowledge pertaining to the "who, what, where, when, why, and how" of MOG-IgG testing, with the aim of facilitating accurate MOGAD diagnosis in clinical practice.
View Article and Find Full Text PDFPerspective on the 65-Year Anniversary of the Discovery of Cytomegalovirus.
Viruses
January 2025
Emeritus, Department of Microbiology & Immunology, Stanford Medical School, Stanford University, Stanford, CA 94305, USA.
This volume presents research and reviews bringing forward new insights into cytomegalovirus (CMV) pathogenesis and biology; CMV is a herpesvirus that has long been recognized as being medically significant [...
View Article and Find Full Text PDFSpecial Issue: Recent Advances in Microglia Research.
Int J Mol Sci
January 2025
Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Viale Pieraccini 6, 50139 Firenze, Italy.
This Editorial introduces the new Special Issue, published in the and entitled "Recent Advances in Microglia Research", which covers this important topic with a collection of five valuable contributions: three Original Research Articles and two Reviews [...
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!